Comparison of Fentanyl-Based Rapid Onset Opioids for the Relief of Breakthrough Cancer Pain: Drug Price Based on Effect Size
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objective: With the advancement of cancer treatments and increased life expectancy, managing breakthrough cancer pain (BTcP) is essential to improve the quality of life for cancer patients. This study aimed to compare the major rapid onset opioids in Korea based on their characteristics and costs to determine the best option for each patient. Methods: Based on sales information from IQVIA-MIDAS, sublingual fentanyl tablet (SLF), fentanyl buccal tablet (FBT), and oral transmucosal fentanyl citrate (OTFC) were selected as the top three drugs for the treatment of BTcP in Korea, considering them the most comparable drugs. The cost and cost-pain relief ratio of the drugs for short-term (1 month) and long-term (1 year) treatment were compared and the ease of administration based on various factors, including pharmacokinetics, onset of action, and administration procedures were evaluated. Results: SLF was evaluated as the best overall in terms of rapid onset of action, ease of administration, and drug cost and also had the highest market share. SLF had the lowest cost pain relief ratio for both the initial and supplemental treatment for the 1- month pain intensity difference 15 (PID15) ratio. However, for the 1-month PID30 ratio, SLF was not superior to OTFC or FBT. The longer the breakthrough cancer pain duration, the more cost-effective the other rapid onset opioids. Conclusion: The rapid onset opioids that fit the patient’s breakthrough cancer pain pattern have the best cost-effectiveness.
Abstract
Background and Objective: With the advancement of cancer treatments and increased life expectancy, managing breakthrough cancer pain (BTcP) is essential to improve the quality of life for cancer patients. This study aimed to compare the major rapid onset opioids in Korea based on their characteristics and costs to determine the best option for each patient. Methods: Based on sales information from IQVIA-MIDAS, sublingual fentanyl tablet (SLF), fentanyl buccal tablet (FBT), and oral transmucosal fentanyl citrate (OTFC) were selected as the top three drugs for the treatment of BTcP in Korea, considering them the most comparable drugs. The cost and cost-pain relief ratio of the drugs for short-term (1 month) and long-term (1 year) treatment were compared and the ease of administration based on various factors, including pharmacokinetics, onset of action, and administration procedures were evaluated. Results: SLF was evaluated as the best overall in terms of rapid onset of action, ease of administration, and drug cost and also had the highest market share. SLF had the lowest cost pain relief ratio for both the initial and supplemental treatment for the 1- month pain intensity difference 15 (PID15) ratio. However, for the 1-month PID30 ratio, SLF was not superior to OTFC or FBT. The longer the breakthrough cancer pain duration, the more cost-effective the other rapid onset opioids. Conclusion: The rapid onset opioids that fit the patient’s breakthrough cancer pain pattern have the best cost-effectiveness.
참고문헌 (25)
- "cancer trend report 2021"[URL]
- Davies AN, "The management of cancer-related breakthrough pain : recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland", Eur J Pain, 13(4), pp.331~338 (2009)
- Koh S, "Assessment, management, and barriers of breakthrough cancer pain: a nationwide study in Korea", Support Care Cancer, 27, pp.eP064~ (2019)
- Davies A, "Breakthrough Cancer Pain : An Observational Study of 1000 European Oncology Patients", J Pain Symptom Manage, 46(5), pp.619~628 (2013)
- 배상병, "암성 통증의 약물치료", 대한내과학회지, 93(3), pp.260~265 (2018), 대한내과학회
- Bennett D, "Consensus panel recommendations for the assessment and management of breakthrough pain : Part 2 Management", P and T, 30(6), pp.354~361 (2005)
- "Abuse of opioid, are we safe?"[URL]
- 서민석, "돌발성 암성 통증", Journal of Hospice and Palliative Care, 18(1), pp.1~8 (2015), 한국호스피스완화의료학회[DOI]
- "Quintiles and IMS Health"[URL]
- Ju, C, "Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study", Lancet Public Health, 7(4), pp.e335~46 (2022)
- "Cancer Pain Management Clinical Practice Guidelines 2018"[URL]
- 신진영, "돌발성 암성 통증 약물 선택 요인과 사용 경험: 의사 대상 설문조사", Journal of Hospice and Palliative Care, 21(1), pp.9~13 (2018), 한국호스피스완화의료학회[DOI]
- Mercadante S, "Breakthrough pain and its treatment : critical review and recommendations of IOPS(Italian Oncologic Pain Survey)expert group", Support Care Cancer, 24(2), pp.961~968 (2016)
- 이영선, "암 환자의 삶의 질에 영향을 미치는 재정 관련 어려움 요인", 한국산학기술학회논문지, 21(10), pp.299~307 (2020), 한국산학기술학회[DOI]
- Simon SM, "A review of rapid-onset opioids for breakthrough pain in patients with cancer", J Opioid Manag, 10(3), pp.207~215 (2014)
- Cortesi PA, "Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment", PLoS One, 12(6), pp.e0179523~ (2017)
- England R, "How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion", BMJ Support Palliat Care, 1(3), pp.349~351 (2011)
- Janknegt R, "Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis", Eur J Hosp Pharm, 25(3), pp.e2~ (2018)
- Zeppetella G, "A network metaanalysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes", J Pain Symptom Manage, 47(4), pp.772~785 (2014)
- Hayan Kwon, "Cost-effectiveness analysis of opioid analgesics for treatment of breakthrough pain in cancer patients", M.S, pp.2012
- Giuliani J, "The role of fentanyl in the treatment of breakthrough cancer pain : Different biotechnologies, different results and different drug costs", J Oncol Pharm Pract, 27(2), pp.445~447 (2021)
- Shin J, "Validation of the Korean Version of the Breakthrough Pain Assessment Tool in Cancer Patients", J Pain Symptom Manage, 54(3), pp.361~367 (2017)
- Mi-Young Kwon, "Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients", The Korean Journal of Internal Medicine, 33(3), pp.577~584 (2018), 대한내과학회[DOI]
- Choi YJ, "Factors associated with Breakthrough Pain in Cancer Patients", M.S, pp.2019
- Kang JH, "Interference with daily functioning by breakthrough pain in patients with cancer", Support Care Cancer, 28(11), pp.5177~5183 (2020)